AGLE
Aeglea BioTherapeutics Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 11-08-2018 | 08-09-2018 | 05-08-2018 | 03-13-2018 | 11-07-2017 | 08-09-2017 | 05-09-2017 | |
|---|---|---|---|---|---|---|---|
| Actual EPS | -0.54 | -0.46 | -0.49 | -0.38 | -0.48 | -0.47 | -0.47 |
| Consensus EPS | -0.41 | -0.37 | -0.54 | -0.67 | -0.59 | -0.55 | |
| Estimated EPS | -0.41 | -0.37 | -0.54 | -0.67 | -0.59 | -0.55 | |
| Number of Estimates | 1 | 1 | 1 | 1 | 1 | 1 | |
| EPS Surprise | -$0.13 | -$0.09 | $0.05 | $0.19 | $0.12 | $0.08 |
Stats
Summary
Aeglea BioTherapeutics Inc is a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism, which will transform the lives of patients with inborn errors of metabolism and cancer.
Market Cap: 111 Million
Primary Exchange: NASDAQ Global Market
Website: http://www.aegleabio.com
Shares Outstanding: 16.6 Million
Float: 16.2 Million
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 38.4 Thousand
Ethical Flags
Longest drawdown: 759 trading days
From: 2016-04-08 To: 2019-02-21
Lowest Point:
Healthcare and Tech tops midday movers
via: SeekingAlpha at 2019-02-06 12:52:37:000
Gainers: MacroGenics (NASDAQ: MGNX ) +129% . Snap (NYSE: SNAP ) +24% . Jason Industries (NASDAQ: JASN ) +23% . Bionano Genomics (NASDAQ: BNGO ) +16% . Proteostasis Therapeutics (NASDAQ: PTI ) +16% . Plantronics (NYSE: PLT ) +15% . Neon Therapeutics (NASDAQ: NTGN ) +15% . MaxLi… read more...
Healthcare and Tech tops midday movers
via: SeekingAlpha at 2019-02-06 12:52:37:000
Gainers: MacroGenics (NASDAQ: MGNX ) +129% . Snap (NYSE: SNAP ) +24% . Jason Industries (NASDAQ: JASN ) +23% . Bionano Genomics (NASDAQ: BNGO ) +16% . Proteostasis Therapeutics (NASDAQ: PTI ) +16% . Plantronics (NYSE: PLT ) +15% . Neon Therapeutics (NASDAQ: NTGN ) +15% . MaxLi… read more...
Healthcare and Tech tops midday movers
via: SeekingAlpha at 2019-02-06 12:52:37:000
Gainers: MacroGenics (NASDAQ: MGNX ) +129% . Snap (NYSE: SNAP ) +24% . Jason Industries (NASDAQ: JASN ) +23% . Bionano Genomics (NASDAQ: BNGO ) +16% . Proteostasis Therapeutics (NASDAQ: PTI ) +16% . Plantronics (NYSE: PLT ) +15% . Neon Therapeutics (NASDAQ: NTGN ) +15% . MaxLi… read more...
ATVI, EA among premarket losers
via: SeekingAlpha at 2019-02-06 09:27:59:000
Arlo Technologies (NYSE: ARLO ) -31% on Q4 earnings . More news on: Arlo Technologies, CCA Industries Inc, Catabasis Pharmaceuticals, Stocks on the move, Read more … read more...
ATVI, EA among premarket losers
via: SeekingAlpha at 2019-02-06 09:27:59:000
Arlo Technologies (NYSE: ARLO ) -31% on Q4 earnings . More news on: Arlo Technologies, CCA Industries Inc, Catabasis Pharmaceuticals, Stocks on the move, Read more … read more...
ATVI, EA among premarket losers
via: SeekingAlpha at 2019-02-06 09:27:59:000
Arlo Technologies (NYSE: ARLO ) -31% on Q4 earnings . More news on: Arlo Technologies, CCA Industries Inc, Catabasis Pharmaceuticals, Stocks on the move, Read more … read more...
Aeglea Biotherapeutics prices $60M equity offering
via: SeekingAlpha at 2019-02-06 05:20:21:000
Aeglea BioTherapeutics (NASDAQ: AGLE ) has priced public offering of 3.75M common stock at $8.00 per share, for expected gross proceeds of ~$60M. More news on: Aeglea BioTherapeutics, Healthcare stocks news, Read more … read more...
Aeglea Biotherapeutics prices $60M equity offering
via: SeekingAlpha at 2019-02-06 05:20:21:000
Aeglea BioTherapeutics (NASDAQ: AGLE ) has priced public offering of 3.75M common stock at $8.00 per share, for expected gross proceeds of ~$60M. More news on: Aeglea BioTherapeutics, Healthcare stocks news, Read more … read more...
Aeglea Biotherapeutics prices $60M equity offering
via: SeekingAlpha at 2019-02-06 05:20:21:000
Aeglea BioTherapeutics (NASDAQ: AGLE ) has priced public offering of 3.75M common stock at $8.00 per share, for expected gross proceeds of ~$60M. More news on: Aeglea BioTherapeutics, Healthcare stocks news, Read more … read more...
Aeglea Biotherapeutics Has Potential In Rare Diseases; We Remain Neutral
via: SeekingAlpha at 2019-01-07 09:03:55:000
Aeglea Biotherapeutics ( AGLE ) is a microcap orphan disease targeted company with a single lead product candidate that just started phase 3 study in ARG1 deficiency disease. The company recently reported positive data from a phase 1/2 study. ARG1-D is an ultrarare pediatric disease with an un… read more...
Aeglea Biotherapeutics Has Potential In Rare Diseases; We Remain Neutral
via: SeekingAlpha at 2019-01-07 09:03:55:000
Aeglea Biotherapeutics ( AGLE ) is a microcap orphan disease targeted company with a single lead product candidate that just started phase 3 study in ARG1 deficiency disease. The company recently reported positive data from a phase 1/2 study. ARG1-D is an ultrarare pediatric disease with an un… read more...
Aeglea Biotherapeutics Has Potential In Rare Diseases; We Remain Neutral
via: SeekingAlpha at 2019-01-07 09:03:55:000
Aeglea Biotherapeutics ( AGLE ) is a microcap orphan disease targeted company with a single lead product candidate that just started phase 3 study in ARG1 deficiency disease. The company recently reported positive data from a phase 1/2 study. ARG1-D is an ultrarare pediatric disease with an un… read more...
Midday Gainers / Losers
via: SeekingAlpha at 2018-12-24 11:55:18:000
Gainers: MINDBODY (NASDAQ: MB ) +67% . Adial Pharmaceuticals (NASDAQ: ADIL ) +31% . Renren (NYSE: RENN ) +17% . Destination Maternity (NASDAQ: DEST ) +16% . Savara (NASDAQ: SVRA ) +16% . Dova Pharmaceuticals (NASDAQ: DOVA ) +15% . Aphria (NYSE: APHA ) +14% . Provention Bio (NA… read more...
Midday Gainers / Losers
via: SeekingAlpha at 2018-12-24 11:55:18:000
Gainers: MINDBODY (NASDAQ: MB ) +67% . Adial Pharmaceuticals (NASDAQ: ADIL ) +31% . Renren (NYSE: RENN ) +17% . Destination Maternity (NASDAQ: DEST ) +16% . Savara (NASDAQ: SVRA ) +16% . Dova Pharmaceuticals (NASDAQ: DOVA ) +15% . Aphria (NYSE: APHA ) +14% . Provention Bio (NA… read more...
Midday Gainers / Losers
via: SeekingAlpha at 2018-12-24 11:55:18:000
Gainers: MINDBODY (NASDAQ: MB ) +67% . Adial Pharmaceuticals (NASDAQ: ADIL ) +31% . Renren (NYSE: RENN ) +17% . Destination Maternity (NASDAQ: DEST ) +16% . Savara (NASDAQ: SVRA ) +16% . Dova Pharmaceuticals (NASDAQ: DOVA ) +15% . Aphria (NYSE: APHA ) +14% . Provention Bio (NA… read more...
Midday Gainers / Losers
via: SeekingAlpha at 2018-12-24 11:55:18:000
Gainers: MINDBODY (NASDAQ: MB ) +67% . Adial Pharmaceuticals (NASDAQ: ADIL ) +31% . Renren (NYSE: RENN ) +17% . Destination Maternity (NASDAQ: DEST ) +16% . Savara (NASDAQ: SVRA ) +16% . Dova Pharmaceuticals (NASDAQ: DOVA ) +15% . Aphria (NYSE: APHA ) +14% . Provention Bio (NA… read more...
Aeglea Bio initiates late-stage study of pegzilarginase in arginase 1 deficiency
via: SeekingAlpha at 2018-12-11 16:40:56:000
Aeglea BioTherapeutics (NASDAQ: AGLE ) announces the design of a Phase 3 clinical trial, PEACE, evaluating lead candidate pegzilarginase in patients with arginase 1 deficiency. Dosing should commence in Q2 2019 with topline data expected in Q1 2021. More news on: Aeglea BioTherapeutics, … read more...
Aeglea Bio initiates late-stage study of pegzilarginase in arginase 1 deficiency
via: SeekingAlpha at 2018-12-11 16:40:56:000
Aeglea BioTherapeutics (NASDAQ: AGLE ) announces the design of a Phase 3 clinical trial, PEACE, evaluating lead candidate pegzilarginase in patients with arginase 1 deficiency. Dosing should commence in Q2 2019 with topline data expected in Q1 2021. More news on: Aeglea BioTherapeutics, … read more...
Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow
via: SeekingAlpha at 2018-11-29 10:23:15:000
The following slide deck was published by Aeglea BioTherapeutics in conjunction with this Read more … read more...
Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow
via: SeekingAlpha at 2018-11-29 10:23:15:000
The following slide deck was published by Aeglea BioTherapeutics in conjunction with this Read more … read more...
Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow
via: SeekingAlpha at 2018-11-29 10:23:15:000
The following slide deck was published by Aeglea BioTherapeutics in conjunction with this Read more … read more...
Aeglea BioTherapeutics misses by $0.10
via: SeekingAlpha at 2018-11-08 08:32:30:000
Aeglea BioTherapeutics (NASDAQ: AGLE ): Q3 GAAP EPS of -$0.52 misses by $0.10. More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Aeglea BioTherapeutics misses by $0.10
via: SeekingAlpha at 2018-11-08 08:32:30:000
Aeglea BioTherapeutics (NASDAQ: AGLE ): Q3 GAAP EPS of -$0.52 misses by $0.10. More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Aeglea BioTherapeutics misses by $0.10
via: SeekingAlpha at 2018-11-08 08:32:30:000
Aeglea BioTherapeutics (NASDAQ: AGLE ): Q3 GAAP EPS of -$0.52 misses by $0.10. More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Aeglea Bio's pegzilarginase shows positive effect in Phase 1/2 ARG1-D study
via: SeekingAlpha at 2018-10-17 10:51:01:000
Preliminary results from a Phase 1/2 clinical trial evaluating Aeglea BioTherapeutics' ( AGLE -4.2% ) lead candidate pegzilarginase in patients with rare inherited disorder called Arginase 1 Deficiency (ARG1-D) showed a treatment effect. The data were presented at the ASHG Conference in… read more...
Aeglea Bio's pegzilarginase shows positive effect in Phase 1/2 ARG1-D study
via: SeekingAlpha at 2018-10-17 10:51:01:000
Preliminary results from a Phase 1/2 clinical trial evaluating Aeglea BioTherapeutics' ( AGLE -4.2% ) lead candidate pegzilarginase in patients with rare inherited disorder called Arginase 1 Deficiency (ARG1-D) showed a treatment effect. The data were presented at the ASHG Conference in… read more...
Aeglea Bio's pegzilarginase shows positive effect in Phase 1/2 ARG1-D study
via: SeekingAlpha at 2018-10-17 10:51:01:000
Preliminary results from a Phase 1/2 clinical trial evaluating Aeglea BioTherapeutics' ( AGLE -4.2% ) lead candidate pegzilarginase in patients with rare inherited disorder called Arginase 1 Deficiency (ARG1-D) showed a treatment effect. The data were presented at the ASHG Conference in… read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-12 08:52:08:000
Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-12 08:52:08:000
Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-12 08:52:08:000
Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-12 08:52:08:000
Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-12 08:52:08:000
Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more … read more...
FDA grants Rare Pediatric Disease designation to Pegzilarginase for Arginase 1 Deficiency
via: SeekingAlpha at 2018-10-01 09:35:08:000
The FDA grants rare pediatric disease designationto Aeglea BioTherapeutics' ( AGLE ), lead product candidate, pegzilarginase, for the treatment of Arginase 1 Deficiency. More news on: Aeglea BioTherapeutics, Healthcare stocks news, Read more … read more...
FDA grants Rare Pediatric Disease designation to Pegzilarginase for Arginase 1 Deficiency
via: SeekingAlpha at 2018-10-01 09:35:08:000
The FDA grants rare pediatric disease designationto Aeglea BioTherapeutics' ( AGLE ), lead product candidate, pegzilarginase, for the treatment of Arginase 1 Deficiency. More news on: Aeglea BioTherapeutics, Healthcare stocks news, Read more … read more...
FDA grants Rare Pediatric Disease designation to Pegzilarginase for Arginase 1 Deficiency
via: SeekingAlpha at 2018-10-01 09:35:08:000
The FDA grants rare pediatric disease designationto Aeglea BioTherapeutics' ( AGLE ), lead product candidate, pegzilarginase, for the treatment of Arginase 1 Deficiency. More news on: Aeglea BioTherapeutics, Healthcare stocks news, Read more … read more...
Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication
via: SeekingAlpha at 2018-09-07 16:31:01:000
News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...
Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication
via: SeekingAlpha at 2018-09-07 16:31:01:000
News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...
Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication
via: SeekingAlpha at 2018-09-07 16:31:01:000
News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...
Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication
via: SeekingAlpha at 2018-09-07 16:31:01:000
News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...
Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication
via: SeekingAlpha at 2018-09-07 16:31:01:000
News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...
Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow
via: SeekingAlpha at 2018-09-05 13:56:58:000
The following slide deck was published by Aeglea BioTherapeutics in conjunction with this Read more … read more...
Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow
via: SeekingAlpha at 2018-09-05 13:56:58:000
The following slide deck was published by Aeglea BioTherapeutics in conjunction with this Read more … read more...
Technology - Top 5 Gainers / Losers as of 2.55 PM (09/05/2018)
via: SeekingAlpha at 2018-09-04 14:55:07:000
Gainers: MNKD +75% . EPIX +32% . NCTY +31% . TA +29% . REPH +22% . More news on: MannKind Corporation, ESSA Pharma, Inc., The9 Limited, Tech stocks news, Stocks on the move, , Read more … read more...
Midday Gainers / Losers (09/04/2018)
via: SeekingAlpha at 2018-09-04 12:42:02:000
Gainers: MNKD +57% . NCTY +29% . TA +29% . REPH +21% . CADC +20% . CDZI +18% . KNSA +16% . EPIX +15% . INNT +14% . NBEV +13% . More news on: MannKind Corporation, The9 Limited, TravelCenters of America LLC, Stocks on the move, , Read more … read more...
Aeglea Bio's pegzilarginase shows treatment effect in arginase 1 deficiency; investors unmoved, shares down 22%
via: SeekingAlpha at 2018-09-04 11:41:08:000
Thinly traded micro cap Aeglea BioTherapeutics ( AGLE -21.9% ) slumps on 75% higher volume in apparent response to its announcement of new data from its Phase 1/2 study of pegzilarginase in patients a rare inherited disorder called arginase 1 deficiency (ARG1-D). The results were present… read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-08-31 08:15:27:000
Noteworthy events for the week of September 2 - 8 for healthcare investors. More news on: BioLife Solutions, Inc., Endocyte, Inc., Soligenix, Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-08-31 08:15:27:000
Noteworthy events for the week of September 2 - 8 for healthcare investors. More news on: BioLife Solutions, Inc., Endocyte, Inc., Soligenix, Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-08-31 08:15:27:000
Noteworthy events for the week of September 2 - 8 for healthcare investors. More news on: BioLife Solutions, Inc., Endocyte, Inc., Soligenix, Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-08-31 08:15:27:000
Noteworthy events for the week of September 2 - 8 for healthcare investors. More news on: BioLife Solutions, Inc., Endocyte, Inc., Soligenix, Inc., Healthcare stocks news, , Read more … read more...
Aeglea BioTherapeutics misses by $0.08, beats on revenue
via: SeekingAlpha at 2018-08-09 08:13:01:000
Aeglea BioTherapeutics (NASDAQ: AGLE ): Q2 EPS of -$0.46 misses by $0.08 . More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Aeglea BioTherapeutics misses by $0.08, beats on revenue
via: SeekingAlpha at 2018-08-09 08:13:01:000
Aeglea BioTherapeutics (NASDAQ: AGLE ): Q2 EPS of -$0.46 misses by $0.08 . More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Aeglea BioTherapeutics misses by $0.08, beats on revenue
via: SeekingAlpha at 2018-08-09 08:13:01:000
Aeglea BioTherapeutics (NASDAQ: AGLE ): Q2 EPS of -$0.46 misses by $0.08 . More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Rubius Therapeutics Proposes Terms For $200 Million IPO
via: SeekingAlpha at 2018-07-09 17:23:20:000
Quick Take Rubius Therapeutics ( RUBY ) intends to raise $200 million from the sale of its common stock in a U.S. IPO, according to an SEC filing . The firm is a very early stage biopharma developing a diverse pipeline of treatments using red blood cells as the primary delivery mechanis… read more...
Rubius Therapeutics Proposes Terms For $200 Million IPO
via: SeekingAlpha at 2018-07-09 17:23:20:000
Quick Take Rubius Therapeutics ( RUBY ) intends to raise $200 million from the sale of its common stock in a U.S. IPO, according to an SEC filing . The firm is a very early stage biopharma developing a diverse pipeline of treatments using red blood cells as the primary delivery mechanis… read more...
Rubius Therapeutics Proposes Terms For $200 Million IPO
via: SeekingAlpha at 2018-07-09 17:23:20:000
Quick Take Rubius Therapeutics ( RUBY ) intends to raise $200 million from the sale of its common stock in a U.S. IPO, according to an SEC filing . The firm is a very early stage biopharma developing a diverse pipeline of treatments using red blood cells as the primary delivery mechanis… read more...
A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals
via: SeekingAlpha at 2018-06-16 09:00:00:000
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...
A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals
via: SeekingAlpha at 2018-06-16 09:00:00:000
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...
A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals
via: SeekingAlpha at 2018-06-16 09:00:00:000
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...
A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals
via: SeekingAlpha at 2018-06-16 09:00:00:000
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...
After Hours Gainers / Losers (05/30/2018)
via: SeekingAlpha at 2018-05-30 17:35:10:000
Top gainers: NGL +13.6% . TLYS +13.0% . KEYS +4.7% . WPG +2.6% . AGLE +1.8% . More news on: NGL Energy Partners LP, Tilly's, Inc., Keysight Technologies Inc., Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (05/30/2018)
via: SeekingAlpha at 2018-05-30 17:35:10:000
Top gainers: NGL +13.6% . TLYS +13.0% . KEYS +4.7% . WPG +2.6% . AGLE +1.8% . More news on: NGL Energy Partners LP, Tilly's, Inc., Keysight Technologies Inc., Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (05/30/2018)
via: SeekingAlpha at 2018-05-30 17:35:10:000
Top gainers: NGL +13.6% . TLYS +13.0% . KEYS +4.7% . WPG +2.6% . AGLE +1.8% . More news on: NGL Energy Partners LP, Tilly's, Inc., Keysight Technologies Inc., Stocks on the move, , News on ETFs, Read more … read more...
Aeglea BioTherapeutics (AGLE) Presents At 2018 UBS Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2018-05-23 14:06:00:000
The following slide deck was published by Aeglea BioTherapeutics in conjunction with this Read more … read more...
Aeglea BioTherapeutics (AGLE) Presents At 2018 UBS Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2018-05-23 14:06:00:000
The following slide deck was published by Aeglea BioTherapeutics in conjunction with this Read more … read more...
Aeglea BioTherapeutics (AGLE) Presents At 2018 UBS Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2018-05-23 14:06:00:000
The following slide deck was published by Aeglea BioTherapeutics in conjunction with this Read more … read more...
Aeglea BioTherapeutics misses by $0.05, beats on revenue
via: SeekingAlpha at 2018-05-08 08:05:05:000
Aeglea BioTherapeutics (NASDAQ: AGLE ): Q1 EPS of -$0.49 misses by $0.05 . More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Aeglea BioTherapeutics misses by $0.05, beats on revenue
via: SeekingAlpha at 2018-05-08 08:05:05:000
Aeglea BioTherapeutics (NASDAQ: AGLE ): Q1 EPS of -$0.49 misses by $0.05 . More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Premarket Gainers as of 9:05 am (04/24/2018)
via: SeekingAlpha at 2018-04-24 09:14:34:000
ATOS +30% on receiving a positive interim review on its Phase 1 study of topical endoxifen in men. More news on: Atossa Genetics, Inc., Weatherford International Ltd., Cadence Design Systems, Inc., , Stocks on the move, Read more … read more...
Premarket Gainers as of 9:05 am (04/24/2018)
via: SeekingAlpha at 2018-04-24 09:14:34:000
ATOS +30% on receiving a positive interim review on its Phase 1 study of topical endoxifen in men. More news on: Atossa Genetics, Inc., Weatherford International Ltd., Cadence Design Systems, Inc., , Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-04-24 08:38:39:000
Aeglea BioTherapeutics (NASDAQ: AGLE ) initiated with Outperform rating and $37 (368% upside) price target at Evercore ISI. Shares up 5% premarket. More news on: Aeglea BioTherapeutics, Alder Biopharmaceuticals Inc., Homology Medicines, Healthcare stocks news, Stocks on the mov… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-04-24 08:38:39:000
Aeglea BioTherapeutics (NASDAQ: AGLE ) initiated with Outperform rating and $37 (368% upside) price target at Evercore ISI. Shares up 5% premarket. More news on: Aeglea BioTherapeutics, Alder Biopharmaceuticals Inc., Homology Medicines, Healthcare stocks news, Stocks on the mov… read more...
Premarket Losers as of 9:05 am (04/19/2018)
via: SeekingAlpha at 2018-04-19 09:24:36:000
ARGS -67% as bails on late-stage study of Rocapuldencel-T in kidney cancer. More news on: Argos Therapeutics, Inc., Aceto Corporation, Helios and Matheson Analytics, Inc., Stocks on the move, , Read more … read more...
Premarket Losers as of 9:05 am (04/19/2018)
via: SeekingAlpha at 2018-04-19 09:24:36:000
ARGS -67% as bails on late-stage study of Rocapuldencel-T in kidney cancer. More news on: Argos Therapeutics, Inc., Aceto Corporation, Helios and Matheson Analytics, Inc., Stocks on the move, , Read more … read more...
Biotech Forum: The Week Ahead
via: SeekingAlpha at 2018-04-16 12:05:10:000
"Life is what happens to us while we are making other plans." - Allen Saunders While the major biotech firms do not start reporting quarterly numbers until later this month, they benefited from the overall solid first week of full first quarter earnings reports crossing the wires this week… read more...
Biotech Forum: The Week Ahead
via: SeekingAlpha at 2018-04-16 12:05:10:000
"Life is what happens to us while we are making other plans." - Allen Saunders While the major biotech firms do not start reporting quarterly numbers until later this month, they benefited from the overall solid first week of full first quarter earnings reports crossing the wires this week… read more...
3 Things In Biotech, April 14: Organovo, Catalyst, And Aeglea Open Up
via: SeekingAlpha at 2018-04-15 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving worl… read more...
3 Things In Biotech, April 14: Organovo, Catalyst, And Aeglea Open Up
via: SeekingAlpha at 2018-04-15 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving worl… read more...
Aeglea BioTherapeutics (AGLE) Clinical Update Call - Slideshow
via: SeekingAlpha at 2018-04-13 13:45:25:000
The following slide deck was published by Aeglea BioTherapeutics in conjunction with this Read more … read more...
Aeglea BioTherapeutics (AGLE) Clinical Update Call - Slideshow
via: SeekingAlpha at 2018-04-13 13:45:25:000
The following slide deck was published by Aeglea BioTherapeutics in conjunction with this Read more … read more...
Aeglea Bio's pegzilarginase shows treatment effect in two Arginase 1 Deficiency patients
via: SeekingAlpha at 2018-04-12 08:20:06:000
Preliminary results from a Phase 1/2 clinical evaluating Aeglea BioTherapeutics' (NASDAQ: AGLE ) AEB1102 (pegzilarginase) in two patients with Arginase 1 Deficiency showed a treatment effect as measured by standardized assessment tools. The data are being presented at the Annual Clinical … read more...
Aeglea Bio's pegzilarginase shows treatment effect in two Arginase 1 Deficiency patients
via: SeekingAlpha at 2018-04-12 08:20:06:000
Preliminary results from a Phase 1/2 clinical evaluating Aeglea BioTherapeutics' (NASDAQ: AGLE ) AEB1102 (pegzilarginase) in two patients with Arginase 1 Deficiency showed a treatment effect as measured by standardized assessment tools. The data are being presented at the Annual Clinical … read more...
After Hours Gainers / Losers (04/10/2018)
via: SeekingAlpha at 2018-04-10 17:37:22:000
Top gainers: VEON +8.4% . SPPI +3.6% . NVTA +3.3% . CBL +2.0% . TVIX +1.2% . More news on: VEON Ltd. ADS, Spectrum Pharmaceuticals, Inc., Invitae, Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (04/10/2018)
via: SeekingAlpha at 2018-04-10 17:37:22:000
Top gainers: VEON +8.4% . SPPI +3.6% . NVTA +3.3% . CBL +2.0% . TVIX +1.2% . More news on: VEON Ltd. ADS, Spectrum Pharmaceuticals, Inc., Invitae, Stocks on the move, , News on ETFs, Read more … read more...
Biotech Forum: The Week Ahead
via: SeekingAlpha at 2018-04-09 10:38:18:000
It has always seemed that a fear of judgment is the mark of guilt and the burden of insecurity. Criss Jami, Killosophy Markets plunged Friday in reaction to escalating trade tensions between the U.S. and China. The major indices ended up again in the red last week. The… read more...
Aeglea Bio sells off after presentation on lead candidate AEB1102; shares down 11%
via: SeekingAlpha at 2018-01-23 15:40:59:000
Investors in thinly traded nano cap Aeglea BioTherapeutics ( AGLE -10.5% ) appear to be taking profits after its 88% runup since the first of December. More news on: Aeglea BioTherapeutics, Healthcare stocks news, Stocks on the move, Read more … read more...
Aeglea Biotherapeutics (AGLE) Presents At BMO Capital Markets 2017 Prescriptions For Success Healthcare Conference - Slideshow
via: SeekingAlpha at 2017-12-15 13:30:12:000
The following slide deck was published by Aeglea BioTherapeutics in conjunction with this Read more … read more...
Your Daily Pharma Scoop: Gilead's Potential, Celgene CAR-T Candidate, Cellectar Soars
via: SeekingAlpha at 2017-12-07 08:00:00:000
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea… read more...
Midday Gainers / Losers
via: SeekingAlpha at 2017-12-01 12:45:32:000
Gainers: AMWD +25% . FMI +22% . CGG +17% . AMPE +20% . AMBA +15% . AGLE +15% . CLRO +14% . XNET +13% . CASI +12% . MARA +12% . More news on: American Woodmark Corporation, Foundation Medicine, Inc., CGG, Stocks on the move, Read more … read more...
Aeglea Biotherapeutics (AGLE) Presents At Society For Immunotherapy Of Cancer - Slideshow
via: SeekingAlpha at 2017-11-13 12:23:27:000
The following slide deck was published by Aeglea BioTherapeutics in conjunction with this Read more … read more...
Aeglea BioTherapeutics beats by $0.07, beats on revenue
via: SeekingAlpha at 2017-11-07 17:08:19:000
Aeglea BioTherapeutics (NASDAQ: AGLE ): Q3 EPS of -$0.48 beats by $0.07 . More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Aeglea BioTherapeutics beats by $0.01, beats on revenue
via: SeekingAlpha at 2017-08-09 16:59:48:000
Aeglea BioTherapeutics (NASDAQ: AGLE ): Q2 EPS of -$0.47 beats by $0.01 . More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Stocks to watch next week
via: SeekingAlpha at 2017-08-05 09:42:29:000
Key events are scheduled for the companies listed below next week. More news on: Marriott International, Inc., CBS Corporation, Tyson Foods Inc., Consumer stocks news, Financial stocks news, Tech stocks news, Healthcare stocks news, Top Breaking stock news, Read more … read more...
Aeglea Bio expects to expand early-stage study of lead product candidate AEB1102 into specific tumors types by Q4/Q1; shares down 8%
via: SeekingAlpha at 2017-05-23 12:41:01:000
In an update to investors, Aeglea BioTherapeutics ( AGLE -7.7% ) reports that its Phase 1 clinical trial assessing the safety, tolerability and pharmacokinetics of lead product candidate AEB1102 has demonstrated clinical proof of mechanism. More news on: Aeglea BioTherapeutics, Healt… read more...
Aeglea BioTherapeutics EPS in-line, misses on revenue
via: SeekingAlpha at 2017-05-09 08:14:07:000
Aeglea BioTherapeutics (NASDAQ: AGLE ): Q1 EPS of -$0.47 in-line. More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|